The intricate relationship between the heightened production of interleukin-1 (IL-1) in severe COVID-19 cases and the activation of NLRP3 inflammatory bodies has prompted extensive exploration within the scientific community to devise novel treatment modalities. The gene discussed is NLRP3; the disease is COVID-19.